Capricor Therapeutics appoints Karimah Es Sabar to Board of Directors

CAPRICOR THERAPEUTICS, INC.

Karimah Es Sabar appointed to Capricor's Board of Directors effective July 23, 2021.
She brings over 35 years of biopharma leadership, drug development, and venture investing experience.
Es Sabar currently serves as CEO and Partner at Quark Venture LP.
She will receive standard non-employee director compensation under Company policies.
Previously held senior roles at CDRD and Sanofi Pasteur; holds degrees in neurochemistry and biochemistry.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karimah Es Sabar

Director

CAPR · CAPRICOR THERAPEUTICS, INC.

Effective: 2021-07-23
Filed: July 27, 2021, 7:59 PM ET

On July 23, 2021, the Board of Directors of Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), elected Karimah Es Sabar as a member of the Company’s Board of Directors (the “Board”) effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Karimah Es Sabar was elected as Director at CAPRICOR THERAPEUTICS, INC..

Action: elected
Role: Director

Exact text from the filing

On July 23, 2021, the Board of Directors of Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), elected Karimah Es Sabar as a member of the Company’s Board of Directors (the “Board”) effective immediately.

View on SEC.gov

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-21-009299

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.